LIQ861 Inhalation Therapy for PAH Again Under FDA Review

LIQ861 Inhalation Therapy for PAH Again Under FDA Review

295829

LIQ861 Inhalation Therapy for PAH Again Under FDA Review

The U.S. Food and Drug Administration (FDA) has accepted an updated application asking that the dry-powder inhalation therapy LIQ861 (treprostinil) be approved to treat pulmonary arterial hypertension (PAH). Liquidia Corporation, the therapy’s developer, first requested approval in April 2020, but the FDA asked for more data on LIQ861 in a complete response letter issued in November. Specifically, the regulatory agency requested more information and clarification of the medicine’s chemistry, manufacturing, and controls. Additional data also had…

You must be logged in to read/download the full post.